



MATERIAL SAFETY DATA SHEET

Revision date: 30-May-2008

Version: 2.2

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Azithromycin Extended Release for Oral Suspension

Trade Name: Zmax
Synonyms: Azithromycin Sustained Release Oral Powder for Suspension
Chemical Family: Azalide
Intended Use: Pharmaceutical product used as Antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance: White to off-white powder

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: May cause eye irritation (based on components) .

Known Clinical Effects: May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Serious allergic reactions, including anaphylaxis, have been reported.

EU Indication of danger: Not classified

Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Additional Information:

Note: For a more detailed discussion of potential health hazards and toxicity see Section 11. This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Azithromycin dihydrate	117772-70-0	Not listed	Not Listed	8.33

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 2 of 11

Version: 2.2

3. COMPOSITION/INFORMATION ON INGREDIENTS

Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4 EEC No. 418-260-2	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Spray dried artificial banana flavor	MIXTURE	Not listed	Not Listed	*
Spray dried artificial cherry flavor	MIXTURE	Not listed	Not Listed	*
Sodium phosphate tribasic, anhydrous	7601-54-9	231-509-8	Not Listed	*
Glyceryl behenate	18641-57-1	242-471-7	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not listed	Not Listed	*
Magnesium hydroxide	1309-42-8	215-170-3	Not Listed	*
Poloxamer 407	9003-11-6	Not listed	Not Listed	*
Xanthan gum	11138-66-2	234-394-2	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.
- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

- Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.
- Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.
- Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
- Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

- Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 3 of 11

Version: 2.2

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8).

Storage Conditions: Store as directed by product packaging.

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 4 of 11

Version: 2.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Azithromycin dihydrate	
Pfizer OEL TWA-8 Hr:	500µg/m ³
Magnesium hydroxide	
Estonia OEL - TWA	Listed
Titanium dioxide	
ACGIH Threshold Limit Value (TWA)	= 10 mg/m ³ TWA
Australia TWA	= 10 mg/m ³ TWA
Austria OEL - MAKs	Listed
Belgium OEL - TWA	Listed
Bulgaria OEL - TWA	Listed
Denmark OEL - TWA	Listed
Estonia OEL - TWA	Listed
France OEL - TWA	Listed
Germany (DFG) - MAK	= 1.5 mg/m ³ MAK
Greece OEL - TWA	Listed
Ireland OEL - TWAs	= 10 mg/m ³ TWA = 4 mg/m ³ TWA
Latvia OEL - TWA	Listed
Lithuania OEL - TWA	Listed
Netherlands OEL - TWA	Listed
OSHA - Final PELs - TWAs:	= 15 mg/m ³ TWA total
Poland OEL - TWA	Listed
Portugal OEL - TWA	Listed
Romania OEL - TWA	Listed
Spain OEL - TWA	Listed
Sweden OEL - TWAs	= 5 mg/m ³ LLV
Colloidal silicon dioxide	
Australia TWA	= 2 mg/m ³ TWA
Austria OEL - MAKs	Listed
Czech Republic OEL - TWA	Listed
Estonia OEL - TWA	Listed
Germany - TRGS 900 - TWAs	= 4 mg/m ³ TWA
Germany (DFG) - MAK	= 4 mg/m ³ MAK
Ireland OEL - TWAs	= 2.4 mg/m ³ TWA = 6 mg/m ³ TWA
Latvia OEL - TWA	Listed
OSHA - Final PELs - Table Z-3 Mineral D:	(80)/(% SiO ₂) mg/m ³ TWA = 20 mppcf TWA
Slovenia OEL - TWA	Listed
Sucrose	
ACGIH Threshold Limit Value (TWA)	= 10 mg/m ³ TWA
Australia TWA	= 10 mg/m ³ TWA
Belgium OEL - TWA	Listed
Bulgaria OEL - TWA	Listed
Estonia OEL - TWA	Listed

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 5 of 11

Version: 2.2

France OEL - TWA	Listed
Ireland OEL - TWAs	= 10 mg/m ³ TWA
Lithuania OEL - TWA	Listed
OSHA - Final PELs - TWAs:	= 15 mg/m ³ TWA total = 5 mg/m ³ TWA
Portugal OEL - TWA	Listed
Spain OEL - TWA	Listed

Analytical Method: Analytical method available for Azithromycin. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Powder	Color:	White to off-white
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solubility:	Soluble: Water		
pH:	9.5 - 12.0 (reconstituted) (60 ml)		
Polymerization:			Will not occur

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: Strong oxidizers , Acids

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension

Page 6 of 11

Revision date: 30-May-2008

Version: 2.2

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD50 29.7 g/kg

Glyceryl behenate

Rat Oral LD50 5 g/kg

Magnesium hydroxide

Rat Oral LD50 8500 mg/kg

Rat Intraperitoneal LD50 2780 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg

Rat Subcutaneous LD 50 50 mg/kg

Xanthan gum

Rat Oral LD50 > 5000 mg/kg

Azithromycin dihydrate

Mouse (F) Oral LD50 4000 mg/kg

Mouse (M) Oral LD50 3000 mg/kg

Rat Oral LD50 > 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Magnesium hydroxide

Eye Irritation Rabbit Moderate

Azithromycin dihydrate

Antigenicity- Active anaphylaxis Guinea Pig Negative

Antigenicity- Passive cutaneous anaphylaxis Rabbit Negative

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Azithromycin dihydrate

6 Month(s) Rat Oral 10 mg/kg/day LOEL Liver

6 Month(s) Dog Oral 10 mg/kg/day LOEL Liver

1 Month(s) Rat Intravenous 5 mg/kg/day NOEL Liver

1 Month(s) Dog Intravenous 5 mg/kg/day NOEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Azithromycin dihydrate

Reproductive & Fertility Rat Oral 10 mg/kg/day NOEL Fertility

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 7 of 11

Version: 2.2

11. TOXICOLOGICAL INFORMATION

Prenatal & Postnatal Development Mouse Oral 40 mg/kg/day NOEL Not Teratogenic
Prenatal & Postnatal Development Rat Oral 40 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Azithromycin dihydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Cytogenetics Mouse Lymphoma Negative
In Vitro Cytogenetics Mouse Negative
In Vitro Cytogenetics Human Lymphocytes Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Colloidal silicon dioxide

IARC: Group 3 (Not Classifiable)

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)
OSHA: Present

12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to mainly reside in the aquatic environment and slowly degrade.

Mobility, Persistence and Degradability: Azithromycin half life < 28 days (Aerobic Biodegradation - Water)

Bioaccumulation and Toxicity: The active ingredient in this formulation has low potential to bioaccumulate and long-term adverse effects to aquatic organisms are not expected. See aquatic toxicity data, below.

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension

Revision date: 30-May-2008

Page 8 of 11

Version: 2.2

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Azithromycin dihydrate

<i>Daphnia Magna</i>	OECD	EC50	48 Hours	120 mg/L
<i>Hyallolella azteca</i>	OECD	LC50	96 Hours	> 120 mg/L
Rainbow Trout	OECD	LC50	96 Hours	> 84 mg/L
Green Algae	OECD	EC50	72 Hours	0.0037 mg/L

Aquatic Toxicity Comments:

A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Azithromycin dihydrate

<i>Aspergillus niger</i> (Fungus)	OECD	MIC	> 1000 mg/L
<i>Trichoderma viride</i> (Fungus)	OECD	MIC	> 1000 mg/L
<i>Clostridium perfringens</i> (Bacterium)	OECD	MIC	2.0 mg/L
<i>Bacillus subtilis</i> (Bacterium)	OECD	MIC	2.0 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 9 of 11

Version: 2.2

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sodium phosphate tribasic, anhydrous

CERCLA/SARA Hazardous Substances
and their Reportable Quantities:

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

EU EINECS/ELINCS List

= 2270 kg final RQ listed under Sodium phosphate, tribasic

= 5000 lb final RQ listed under Sodium phosphate, tribasic

Present

Present

Schedule 5

Schedule 6

231-509-8

Glyceryl behenate

Australia (AICS):

EU EINECS/ELINCS List

Present

242-471-7

Hydroxypropyl cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

XU

Present

Magnesium hydroxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present

Present

215-170-3

Poloxamer 407

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

XU

Present

Xanthan gum

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

XU

Present

234-394-2

Titanium dioxide

Inventory - United States TSCA - Sect. 8(b)

Present

MATERIAL SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 30-May-2008

Page 10 of 11

Version: 2.2

Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Colloidal silicon dioxide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4 EEC No. 418-260-2
Water	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2
Sucrose	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

16. OTHER INFORMATION

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 - Disposal Considerations.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

MATERIAL SAFETY DATA SHEET

**Material Name: Azithromycin Extended Release for Oral
Suspension**
Revision date: 30-May-2008

Page 11 of 11

Version: 2.2
